Formulation Development

In the pharmaceutical industry, every capsule and tablet begins with a concept. Transforming that idea into a tangible product requires an expert manufacturing partner. Natoli stands out as a leader in pharmaceutical equipment and services, providing a comprehensive journey from formulation to full-scale production.

Synthetic oligonucleotide therapeutics, such as antisense oligonucleotides (ASOs) and small interfering RNAs (si-RNAs), require thorough analysis to establish purity and quality.

Next-generation fluorescent imaging solution for the assurance of monoclonality and automated confluence across diverse cell types

Demonstrating that cell lines are monoclonal – or that a gene was edited as expected – can be a time-consuming and highly-subjective process when relying on conventional technologies. The CloneSelect® Imager and CloneSelect® Imager FL are a high-throughput automated solutions for imaging and analyzing mammalian cells. Tracking the formation of a colony from a single cell is effortless as barcoded plates are tracked over time. Automated acquisition and analysis provides accurate, objective, and consistent results.

Optimize Your GC Analysis with Zebron GC Columns

Zebron GC columns are engineered with quality of analysis in mind to better support scientists' research and regulatory analysis for environmental, food safety, food quality, forensics, pharma, fuels, and specialty chemicals.

Evaluating small and large molecule therapeutics within cellular environments is essential to understanding their efficacy, potency, and safety within a complex biological system.

Nanoform’s proprietary bionanoparticle technology can deliver large-molecule drug particles as small as 50 nm while retaining biological activity. This can not only enable more patient-friendly approaches to drug delivery, but also potentially higher loads of active ingredients.

The systems can be provided in sterile, toxic or sterile toxic arrangements with the great advantage of being 100 % scalable.

When it comes to solid dosage formulations, the most common challenge formulators face is poor solubility. In numbers: 70% of drugs in development are poorly soluble.